Clinical Trial Update: A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a completed Phase I/II study evaluating the combination of bexarotene and gefitinib (Iressa) for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bexarotene (Bexarotene)
• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: Stanford University | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED